drospirenone has been researched along with Cardiovascular Diseases in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (29.17) | 29.6817 |
| 2010's | 15 (62.50) | 24.3611 |
| 2020's | 2 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Dožić, B; Dožić, I; Srebro, D; Vujović, S; Đogo, A | 1 |
| Colli, E; Palacios, S; Regidor, PA | 1 |
| Bodur, S; Dundar, O; Kanat-Pektas, M; Kinci, MF; Tutuncu, L | 1 |
| Ambrosio, D; Cerreto, FV; De Franciscis, P; Labriola, D; Leo, S; Luisi, A; Mainini, G; Russo, C; Santangelo, F; Torella, M | 1 |
| Bajuk Studen, K; Jensterle Sever, M; Pfeifer, M | 1 |
| El-Haggar, SM; Mostafa, TM | 1 |
| Dinger, J; Heinemann, K; Möhner, S | 1 |
| Bardenheuer, K; Dinger, J; Heinemann, K | 1 |
| Bottiglieri, P; Colao, A; Colarieti, G; Giallauria, F; Muscogiuri, G; Orio, F; Palomba, S; Predotti, P; Savastano, S; Tafuri, D | 1 |
| Fini, M; Gambacciani, M; Mammi, C; Rosano, GMC; Russo, N; Spoletini, I; Vitale, C; Volterrani, M | 1 |
| Battaglia, C; Busacchi, P; Cianciosi, A; Facchinetti, F; Mancini, F; Persico, N | 1 |
| Assmann, A; Bardenheuer, K; Dinger, JC | 1 |
| Fruzzetti, F; Gambacciani, M; Genazzani, AR; Lazzarini, V; Parrini, D; Perini, D | 1 |
| Genazzani, AR; Simoncini, T | 1 |
| Boschitsch, E; Magometschnigg, D; Mayerhofer, S | 1 |
| Arslanian, S; Lee, S; Sutton-Tyrrell, K; Tfayli, H; Ulnach, JW | 1 |
| Cremer, M; Friedman, J; Huang, X; Jelani, QU; Jian, J; Katz, SD; Shah, S | 1 |
| Arangino, S; Cagnacci, A; Ferrari, S; Napolitano, A; Piacenti, I; Volpe, A | 1 |
| He, FJ; MacGregor, GA | 1 |
| Christiansen, C; Tankó, LB | 1 |
| Tsuda, K | 1 |
| Marazzi, G; Rosano, GM; Vitale, C; Volterrani, M | 1 |
| Motivala, A; Pitt, B | 1 |
| Skouby, SO | 1 |
7 review(s) available for drospirenone and Cardiovascular Diseases
| Article | Year |
|---|---|
Cardiovascular risk and subclinical cardiovascular disease in polycystic ovary syndrome.
Topics: Adolescent; Adult; Androstenes; Atherosclerosis; Cardiovascular Diseases; Carotid Intima-Media Thickness; Coronary Artery Disease; Female; Humans; Hypertension; Incretins; Insulin Resistance; Life Style; Metformin; Middle Aged; Obesity; Polycystic Ovary Syndrome; Postmenopause; Renin-Angiotensin System; Risk Factors; Sleep Apnea, Obstructive; Thiazolidinediones; Vascular Stiffness; Weight Reduction Programs | 2013 |
A review of the cardiovascular and breast actions of drospirenone in preclinical studies.
Topics: Androstenes; Animals; Breast; Breast Neoplasms; Cardiovascular Diseases; Cardiovascular System; Estrogen Replacement Therapy; Estrogens; Female; Humans; Menopause; Mineralocorticoid Receptor Antagonists; Progesterone Congeners; Progestins; Risk Factors | 2010 |
Hypertension in women: the role of progesterone and aldosterone.
Topics: Aged; Aldosterone; Androstenes; Animals; Cardiovascular Diseases; Diet, Sodium-Restricted; Estradiol; Estrogens; Female; Humans; Hypertension; Middle Aged; Mineralocorticoid Receptor Antagonists; Natriuresis; Progesterone; Progesterone Congeners; Renin-Angiotensin System; Risk Factors; Sex Characteristics | 2010 |
Importance of controlling blood pressure.
Topics: Androstenes; Antihypertensive Agents; Cardiovascular Diseases; Clinical Trials as Topic; Diet, Sodium-Restricted; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Progesterone Congeners; Risk Factors; Sodium Chloride, Dietary | 2005 |
Menopause and cardiovascular disease: the evidence.
Topics: Androstenes; Cardiovascular Diseases; Diabetes Mellitus; Estrogen Replacement Therapy; Female; Humans; Hypertension; Menopause; Mineralocorticoid Receptor Antagonists; Risk Factors; Weight Gain | 2007 |
Drospirenone for oral contraception and hormone replacement therapy: are its cardiovascular risks and benefits the same as other progestogens?
Topics: Androstenes; Cardiovascular Diseases; Contraceptives, Oral; Hormone Replacement Therapy; Humans; Mineralocorticoid Receptor Antagonists; Progestins; Risk Assessment | 2007 |
The rationale for a wider range of progestogens.
Topics: Androstenes; Biological Availability; Breast Neoplasms; Cardiovascular Diseases; Contraindications; Endometrial Neoplasms; Estranes; Estrogen Replacement Therapy; Female; Gonanes; Humans; Nandrolone; Osteoporosis, Postmenopausal; Pregnanes; Primary Prevention; Progestins; Treatment Outcome | 2000 |
8 trial(s) available for drospirenone and Cardiovascular Diseases
| Article | Year |
|---|---|
Efficacy and cardiovascular safety of the new estrogen-free contraceptive pill containing 4 mg drospirenone alone in a 24/4 regime.
Topics: Adult; Androstenes; Blood Pressure; Cardiovascular Diseases; Contraception; Female; Humans; Middle Aged; Mineralocorticoid Receptor Antagonists | 2020 |
The effects of different therapeutic modalities on cardiovascular risk factors in women with polycystıc ovary syndrome: A randomızed controlled study.
Topics: Adult; Androstenes; Apolipoproteins B; Blood Glucose; C-Reactive Protein; Cardiovascular Diseases; Drug Therapy, Combination; Ethinyl Estradiol; Female; Homocysteine; Humans; Hypoglycemic Agents; Insulin Resistance; Metabolic Syndrome; Metformin; Mineralocorticoid Receptor Antagonists; Peptide Fragments; Plasminogen Activator Inhibitor 1; Polycystic Ovary Syndrome; Reproductive Control Agents; Risk Factors; Young Adult | 2018 |
Drospirenone plus estradiol and the risk of serious cardiovascular events in postmenopausal women.
Topics: Androstenes; Antihypertensive Agents; Cardiovascular Diseases; Drug Therapy, Combination; Estradiol; Estrogen Replacement Therapy; Estrogens; Female; Follow-Up Studies; Humans; Incidence; Middle Aged; Mineralocorticoid Receptor Antagonists; Postmenopause; Proportional Hazards Models; Prospective Studies; Regression Analysis; Risk Factors; Single-Blind Method; Thromboembolism | 2016 |
Oral contraceptives versus physical exercise on cardiovascular and metabolic risk factors in women with polycystic ovary syndrome: a randomized controlled trial.
Topics: Adult; Androstenes; Cardiovascular Diseases; Carotid Intima-Media Thickness; Contraceptives, Oral; Ethinyl Estradiol; Exercise; Female; Humans; Hyperandrogenism; Metabolic Diseases; Polycystic Ovary Syndrome; Risk Factors; Young Adult | 2016 |
Effect of hormone replacement therapy with the anti-mineralocorticoid progestin Drospirenone compared to tibolone on endothelial function and central haemodynamics in post-menopausal women.
Topics: Androstenes; Blood Pressure Determination; Cardiovascular Diseases; Cells, Cultured; Double-Blind Method; Drug Combinations; Endothelial Cells; Endothelium, Vascular; Estradiol; Female; Hemodynamics; Hormone Replacement Therapy; Humans; Hypertension; Middle Aged; Mineralocorticoid Receptor Antagonists; Norpregnenes; Postmenopause; Progestins; Pulse Wave Analysis; Reference Values; Treatment Outcome | 2017 |
Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome.
Topics: Administration, Oral; Adolescent; Adult; Androgens; Androstenes; Blood Pressure; Cardiovascular Diseases; Cyproterone; Dose-Response Relationship, Drug; Drug Therapy, Combination; Estrogens; Ethinyl Estradiol; Female; Glucose; Humans; Hypoglycemic Agents; Insulin; Lipids; Metformin; Mineralocorticoid Receptor Antagonists; Polycystic Ovary Syndrome; Risk Factors; Young Adult | 2010 |
Drospirenone/ethinyl estradiol versus rosiglitazone treatment in overweight adolescents with polycystic ovary syndrome: comparison of metabolic, hormonal, and cardiovascular risk factors.
Topics: Adolescent; Adrenocorticotropic Hormone; Androstenes; Body Composition; Cardiovascular Diseases; Double-Blind Method; Ethinyl Estradiol; Female; Glucose Clamp Technique; Glucose Tolerance Test; Hemodynamics; Hormones; Humans; Hyperandrogenism; Hypoglycemic Agents; Insulin Resistance; Menstrual Cycle; Mineralocorticoid Receptor Antagonists; Overweight; Polycystic Ovary Syndrome; Risk Factors; Rosiglitazone; Stimulation, Chemical; Thiazolidinediones | 2011 |
Effects of 17beta-oestradiol plus different doses of drospirenone on adipose tissue, adiponectin and atherogenic metabolites in postmenopausal women.
Topics: Absorptiometry, Photon; Adiponectin; Adipose Tissue; Aged; Androstenes; Blood Pressure; Cardiovascular Diseases; Cholesterol, HDL; Double-Blind Method; Drug Therapy, Combination; Estradiol; Female; Humans; Interleukin-6; Middle Aged; Mineralocorticoid Receptor Antagonists; Postmenopause; Risk Factors; Triglycerides | 2005 |
9 other study(ies) available for drospirenone and Cardiovascular Diseases
| Article | Year |
|---|---|
Effects of continuous-combined oral drospirenone- estradiol on blood pressure, body weight & lipid profile in early menopausal women.
Topics: Adult; Androstenes; Blood Pressure; Body Weight; Cardiovascular Diseases; Cholesterol; Estradiol; Female; Humans; Hypertension; Lipids; Menopause; Menopause, Premature; Middle Aged; Retrospective Studies | 2021 |
Low-dose estrogen and drospirenone combination: effects on metabolism and endothelial function in postmenopausal women with metabolic syndrome.
Topics: Androstenes; Blood Pressure; Brachial Artery; Cardiovascular Diseases; Carotid Artery, Common; Carotid Intima-Media Thickness; Cholesterol; Endothelium, Vascular; Estrogens; Ethinyl Estradiol; Female; Humans; Metabolic Syndrome; Middle Aged; Postmenopause; Risk Factors; Triglycerides; Vasodilation | 2013 |
Cardiovascular risk in Egyptian healthy consumers of different types of combined oral contraceptives pills: A comparative study.
Topics: Adiponectin; Adipose Tissue; Adult; Androstenes; Anthropometry; Cardiovascular Diseases; Chemistry, Pharmaceutical; Cholesterol, HDL; Cholesterol, LDL; Contraceptives, Oral, Combined; Cross-Sectional Studies; Drug Combinations; Egypt; Ethinyl Estradiol; Female; Humans; Leptin; Levonorgestrel; Norpregnenes; Resistin; Risk Factors | 2015 |
Cardiovascular risks associated with the use of drospirenone-containing combined oral contraceptives.
Topics: Adult; Androstenes; Cardiovascular Diseases; Cohort Studies; Contraceptives, Oral, Combined; Ethinyl Estradiol; Europe; Female; Follow-Up Studies; Humans; Incidence; Levonorgestrel; Longitudinal Studies; Mineralocorticoid Receptor Antagonists; Patient Reported Outcome Measures; Pharmacovigilance; Progestins; Proportional Hazards Models; Risk Factors | 2016 |
Drospirenone and cardiovascular risk in lean and obese polycystic ovary syndrome patients: a pilot study.
Topics: Adolescent; Adult; Androstenes; Brachial Artery; Cardiovascular Diseases; Contraceptives, Oral; Endothelin-1; Female; Homocysteine; Humans; Insulin; Insulin Resistance; Leptin; Mineralocorticoid Receptor Antagonists; Obesity; Pilot Projects; Polycystic Ovary Syndrome | 2010 |
International Active Surveillance Study of Women Taking Oral Contraceptives (INAS-OC Study).
Topics: Adolescent; Adult; Androstenes; Cardiovascular Diseases; Cohort Studies; Contraceptives, Oral; Ethinyl Estradiol; Female; Humans; Internationality; Population Surveillance; Progestins; Research Design; Young Adult | 2009 |
Oral contraceptive use, iron stores and vascular endothelial function in healthy women.
Topics: Adult; Androstenes; Blood Flow Velocity; Brachial Artery; Cardiovascular Diseases; Contraceptives, Oral; Cross-Sectional Studies; Endothelium, Vascular; Estranes; Female; Ferritins; Gonanes; Humans; Iron; Linear Models; Ultrasonography; Vasodilation; Young Adult | 2011 |
Combined oral contraceptive containing drospirenone does not modify 24-h ambulatory blood pressure but increases heart rate in healthy young women: prospective study.
Topics: Adolescent; Adult; Androstenes; Blood Pressure; Cardiovascular Diseases; Circadian Rhythm; Contraceptives, Oral, Combined; Ethinyl Estradiol; Female; Heart Rate; Humans; Hypertension; Young Adult | 2013 |
A new hormone therapy with drospirenone and NO production in postmenopausal women.
Topics: Androstenes; Animals; Antihypertensive Agents; Cardiovascular Diseases; Estradiol; Humans; Mineralocorticoid Receptor Antagonists; Nitric Oxide; Postmenopause | 2006 |